Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,130,432 shares, an increase of 79.8% from the May 31st total of 628,655 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average trading volume of 279,068 shares, the short-interest ratio is presently 4.1 days.

Institutional Trading of Coeptis Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC increased its holdings in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics during the 3rd quarter valued at $140,000. Marshall Wace LLP acquired a new stake in shares of Coeptis Therapeutics during the 4th quarter valued at $259,000. State Street Corp grew its position in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. 13.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Coeptis Therapeutics currently has an average rating of “Sell”.

Coeptis Therapeutics Stock Performance

ZSQR opened at $12.02 on Thursday. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a 12-month low of $7.25 and a 12-month high of $21.41. The business has a 50 day moving average of $12.17 and a 200-day moving average of $12.65. The stock has a market cap of $618.19 million, a price-to-earnings ratio of -4.77 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.The firm had revenue of $0.11 million for the quarter.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.